Latest Conference Coverage

Dementia-Related Psychosis Places Heavy Burden on Patients and Caretakers

Data from 2 posters presented at AAIC 2020 suggest that there is an unmet need for safe and effective treatments for patients who experience dementia-related psychosis.

Raymond S. Turner, MD, PhD: Safety Results for Nilotinib in Alzheimer

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.

12 Modifiable Risk Factors to Reduce Dementia Risk

Excessive alcohol intake, head injury, and air pollution are among the newest dementia risk factors added to the Lancet Commission report.

Nilotinib Safety Profile Sets Agent Up For Phase 3 Study

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center details his findings from the phase 2 study of nilotinib in patients with Alzheimer disease.

Katrina Celis, MD: Ancestral Genetics and the Impact on Alzheimer Disease Risk

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed her study presented at AAIC 2020 that examined Alzheimer risk associated with APOE ε4 in different genetic populations.

Hypertension, Diabetes, High BMI All Early Life Risk Factors for Dementia

Multiple studies presented at AAIC 2020 highlight and confirm previous hypotheses of the role that early life cardiovascular risk factors play for individuals who develop late life dementia.

VU319 Shows Safe Profile and Potential as M1 Allosteric Modulator for MCI

The data suggests that a planned multiple ascending dose study and a phase 2a proof-of-concept study in patients with mild cognitive impairment could be on the way.

Nilotinib Has Safe and Tolerable Profile in Alzheimer Disease

Results presented virtually at AAIC 2020 support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.

Candesartan Shows Signs of Neuroprotection in Older Adults With MCI and Hypertension

Compared to treatment with lisinopril, those treated with the angiotensin receptor blocker candesartan showed improvements on the Trial Making Test part A and B and Hopkins Verbal Learning Test-Revised delayed recall.

Pimavanserin Reduces Dementia-Related Psychosis Symptoms

Additional data presented at AAIC 2020 shows the clinical benefit pimavanserin has on dementia-related psychosis while the agent awaits a PDUFA date of April 3, 2021.

P-Tau217 May Detect Alzheimer Disease, Brain Amyloidosis, Tauopathy

The performance of p-tau217 was similar to significantly more costly methods, such as PET imaging and measuring cerebrospinal fluid biomarkers.

Influenza, Pneumonia Vaccination May Reduce Alzheimer Disease Risk

A trio of studies presented at AAIC 2020 suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.

Matthew Robbins, MD: Headaches Associated With COVID-19

The director of the Neurology Residency Program at Weill Cornell Medicine highlighted some of the differences in types of headaches that patients with COVID-19 experience, as well as overall takeaways from the pandemic itself.

Fred Cohen, MD: OnabotulinumtoxinA and CGRP Combination Treatment

The internal medicine resident physician at Montefiore Health System provided an overview of the study he and colleagues conducted on patients using onabotulinumtoxinA and CGRP agents in tandem.

Kathleen Digre, MD, on Eye Pain and Photophobia in Migraine

Despite its ranking as a "most bothersome symptom" among migraineurs, eye pain and photophobia often go ignored or under-treated in the headache clinic.

Roger Cady, MD: Rapid Effect of Eptinezumab on Migraine

The head of Neurology Medical at Lundbeck Seattle Biopharmaceuticals offers perspective on the findings and what impact eptinezumab may have on migraine care.

Total Migraine Pain Burden Reduced With Galcanezumab in Post-Hoc Analysis

Treatment with galcanezumab (Emgality; Eli Lilly) was associated with improvements in total pain burden for patients with both chronic and episodic migraine compared to placebo groups.

Matthew Robbins, MD: Residency During COVID-19

The director of the Neurology Residency Program at Weill Cornell Medicine provided insight on the experience residents have had during the COVID-19 pandemic and how it has shaped them for the future.

Chia-Chun Chiang, MD: Collecting Real-World Data Following FDA Approvals

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.

Long-Term Safety Study Confirms Efficacy of ADAM Zolmitriptan in Acute Migraine

The FDA accepted an NDA for Zosano’s ADAM zolmitriptan (Qytripta) in the acute treatment of migraine in early March, with a PDUFA date set for mid-October 2020.

Chia-Chun Chiang, MD: Variations in FDA Approved Migraine Medications

The neurologist at Mayo Clinic in Phoenix, Arizona, discussed the growing variety of treatment options and the progress the migraine community has made on the management of this disease.

Migraine Care During a Pandemic: Takeaways for the Future

In part 2 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, describes the lessons he and his residents have learned during the COVID-19 pandemic and how they'll impact the future of care.

Chia-Chun Chiang, MD: Comparing Ubrogepant Study Results

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed whether her and colleagues recent study results on ubrogepant aligned with previous study findings.

Fred Cohen, MD: Combining CGRPs and OnabotulinumtoxinA for Migraine Prevention

The internal medicine resident physician at Montefiore Health System offers insight into the combined use of CGRP medications and Botox to optimize migraine prevention in patients who have inadequate response with Botox alone.

Neurology and COVID-19: Adapting Specialty Care During the Pandemic

In Part 1 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, shares his experience caring for headache patients in the epicenter of the coronavirus 2019 pandemic.

Gilbert L'Italien, PhD: The Economic Impact of MIDAS Disability Grades in Migraine

The senior VP of Global Health Economics and Outcomes Research and Epidemiology at Biohaven Pharmaceuticals discussed the findings from a poster presentation on the economic impact of migraine disability at AHS 2020.

High Frequency Episodic Migraine Has Similar Burden to Low Frequency Chronic Migraine

Treatment needs of those with high frequency episodic migraine may be similar to those with low frequency chronic migraine.

Ubrogepant Effective for Migraine Patients With Insufficient Triptan Response

The recently approved Allergan agent reported lower rates of functional disability and better overall satisfaction with treatment, as well as similar success for those who did not experience efficacy with triptans.

Matthew Robbins, MD: Experience Adjusting to COVID-19 in Migraine Care

The director of the Neurology Residency Program at Weill Cornell Medicine details his first-hand experience working in the epicenter of the COVID-19 pandemic and how his department adapted.

The Long-Term Impact of Addressing Gender Norms for Men With MS

In Part 2 of this interview, Bryan Davis, PsyD, MS, clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS, details the impact that conversations about masculinity norms in MS can have on future trials and care.